Education
About Us
Working with TipRanks
Follow Us
Portage Biotech (PRTG)
:PRTG
PRTG Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.09 - $23.01
Previous CloseN/A
Volume13.74K
Average Volume (3M)159.11K
Market Cap
$12.98M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Sep 01, 2025EPS EstimateN/A
Last Dividend Ex-Date
Jan 04, 2018Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,278,622
10 Day Avg. Volume16,973
30 Day Avg. Volume159,108
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Portage Biotech Inc News
PRTG FAQ
What was Portage Biotech’s price range in the past 12 months?
Portage Biotech lowest stock price was $2.09 and its highest was $23.01 in the past 12 months.
What is Portage Biotech’s market cap?
Portage Biotech’s market cap is $12.98M.
When is Portage Biotech’s upcoming earnings report date?
Portage Biotech’s upcoming earnings report date is Sep 01, 2025 which is in 32 days.
How were Portage Biotech’s earnings last quarter?
Currently, no data Available
Is Portage Biotech overvalued?
According to Wall Street analysts Portage Biotech’s price is currently Overvalued.
Does Portage Biotech pay dividends?
Portage Biotech pays a Notavailable dividend of $948 which represents an annual dividend yield of N/A. See more information on Portage Biotech dividends here
What is Portage Biotech’s EPS estimate?
Portage Biotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Portage Biotech have?
Portage Biotech has 2,278,622 shares outstanding.
What happened to Portage Biotech’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Portage Biotech?
Currently, no hedge funds are holding shares in PRTG
Company Description
Portage Biotech
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
0.85% Other Institutional Investors
99.15% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---